Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study [0.03%]
晚期/转移性尿路上皮癌和非肌层浸润性膀胱癌患者FGFR变异检测结果的全球ANNAR生物标志物研究分析：3600余例患者的回顾性分析
Nobuaki Matsubara,Yohann Loriot,Severine Banek et al.
Nobuaki Matsubara et al.
Background and objective: Successful fibroblast growth factor receptor alterations (FGFRalt) testing is essential for identifying patients eligible for erdafitinib. This analysis of the global ANNAR biomarker study assess...
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy [0.03%]
预测转移灶靶向治疗联合或不联合雄激素剥夺治疗的基因组标志物
Philip Sutera,Kim Van der Eecken,Yang Song et al.
Philip Sutera et al.
Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). ...
Comparative Impact of Elastic Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy on Concordance of Detection of Clinically Significant Prostate Cancer by International Society of Urological Pathology Grade in Biopsy-naïve Men with Prostate-specific Antigen ≤20 ng/ml and cT1-2 Disease [0.03%]
弹性磁共振影像-经直肠超声融合活检在前列腺特异性抗原≤20ng/ml和cT1-2期初诊患者中对国际病理协会分级的显著性前列腺癌检测一致性的影响比较
Bogdan Adrian Buhas,Adrien Gregoris,Mihaela Iancu et al.
Bogdan Adrian Buhas et al.
Background and objective: Magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) fusion guided biopsy is the cornerstone of prostate cancer (PC) diagnosis. While prior studies have focused on detection rates, the ...
Re: Nicolas A. Soputro, Carter D. Mikesell, Salim K. Younis, et al. Propensity-matched Comparison of Single-port Transvesical Versus Standard Multiport Robotic Radical Prostatectomy. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2025.05.023 [0.03%]
尼古拉·A·索普图罗等：单端口经膀胱机器人辅助前列腺根治术与标准多端口机器人辅助前列腺根治术的倾向匹配比较《 Eur Urol Oncol》在刊。https://doi.org/10.1016/j.euo.2025.05.023
Fabrizio Di Maida,Carlo Andrea Bravi,Marcio Covas Moschovas et al.
Fabrizio Di Maida et al.
Reply to Natália Dalsenter Avilez, Tomás Bernardo Costa Moretti, and Leonardo Oliveira Reis' Letter to the Editor re: Anna Lantz, Ying Li, Stefan Carlsson, et al. Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer-specific Survival-12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial. Eur Urol Oncol. I [0.03%]
关于娜塔莉亚·达岑特·阿维莱兹、汤玛斯·波恩巴多·科斯塔·莫雷蒂及莱昂纳多·奥利韦拉·雷伊斯来信的回复：机器人与开放根治性前列腺切除术在12年随访中前列腺癌特异性生存率差异——LAParoscopic Prostatectomy Robot Open Trial
Anna Lantz,Ying Li,Stefan Carlsson et al.
Anna Lantz et al.
Re: Anna Lantz, Ying Li, Stefan Carlsson, et al. Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer-specific Survival-12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2025.05.004 [0.03%]
机器人与开放根治性前列腺切除术的差异：LAParoscopic Prostatectomy Robot Open Trial长达12年的随访结果（已接收发表）
Natália Dalsenter Avilez,Tomás Bernardo Costa Moretti,Leonardo Oliveira Reis
Natália Dalsenter Avilez
Reply to Fabrizio Di Maida, Carlo Andrea Bravi, Marcio Covas Moschovas, et al's Letter to the Editor re: Nicolas A. Soputro, Carter D. Mikesell, Salim K. Younis, et al. Propensity-matched Comparison of Single-port Transvesical Versus Standard Multiport Robotic Radical Prostatectomy. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2025.0 [0.03%]
Nicolas A. Soputro等关于Fabrizio Di Maida, Carlo Andrea Bravi, Marcio Covas Moschovas等人针对单通道经膀胱与标准多通道机器人辅助前列腺根治术倾向匹配比较来信的回复Eur Urol Oncol. 在线发表。https://doi.org/10.1016/j.euo.2025.0
Nicolas A Soputro,Jihad Kaouk
Nicolas A Soputro
Association Between Race and Detection of Clinically Significant Prostate Cancer in Transperineal and Transrectal Biopsies [0.03%]
种族与经会阴和经直肠活检发现临床显著性前列腺癌之间的关系
Suma Gangidi,Gal Wald,Mary Oakley Strasser et al.
Suma Gangidi et al.
Background and objective: The apex-to-base transperineal (TP) prostate biopsy needle trajectory may better sample the anterior prostate than the transrectal approach. There is evidence that African American men are more l...
Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort [0.03%]
前列腺、乳腺、卵巢和/或胰腺癌的家族史与大型前列腺癌主动监测队列等级重新分类的相关性研究
Claire M de la Calle,Yuezhou Jing,Julia Fountain et al.
Claire M de la Calle et al.
Background and objective: The effect of family history (FH) on prostate cancer active surveillance outcomes is unknown. Our objective is to evaluate FH of prostate, breast, ovarian, and/or pancreatic cancer in a large pro...
Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients [0.03%]
前列腺癌Decipher 1.0和1.1版预后基因表达谱的临床比较：根治术及主动监测患者结果分析
Brendan L Raizenne,Kevin Shee,Janet E Cowan et al.
Brendan L Raizenne et al.
Decipher is a 22-gene genomic risk classifier that utilizes a whole-transcriptome microarray assay to provide a score ranging from 0 to 1. Recently, the individual gene scores that defined Decipher v1.0 were reweighted to define updated Dec...